Oxford Immunotec Global (OXFD) Receives Coverage Optimism Rating of 0.12

Press coverage about Oxford Immunotec Global (NASDAQ:OXFD) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oxford Immunotec Global earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.4734884714409 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Oxford Immunotec Global (NASDAQ:OXFD) opened at $14.06 on Monday. The stock has a market capitalization of $360.71, a PE ratio of -6.96 and a beta of -0.09. Oxford Immunotec Global has a fifty-two week low of $12.19 and a fifty-two week high of $19.51. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.

A number of equities research analysts recently weighed in on the stock. Cowen restated a “buy” rating and set a $19.00 price objective on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. Zacks Investment Research upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. BTIG Research assumed coverage on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. They set a “buy” rating and a $21.00 price objective on the stock. Piper Jaffray Companies cut their price objective on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 31st. Finally, BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Oxford Immunotec Global currently has an average rating of “Hold” and a consensus price target of $19.75.

In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the transaction, the director now directly owns 17,778 shares of the company’s stock, valued at $237,336.30. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 8.11% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://weekherald.com/2018/01/08/oxford-immunotec-global-oxfd-receives-coverage-optimism-rating-of-0-12.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Insider Buying and Selling by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply